Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome

RTX administration was safe and effective in patients with difficult-to-treat NS. One or 2 doses of RTX may be sufficient to deplete B cells and achieve better control of pediatric NS.